

# Peter J Whorwell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4895111/publications.pdf>

Version: 2024-02-01

116  
papers

12,777  
citations

34105

52  
h-index

27406

106  
g-index

117  
all docs

117  
docs citations

117  
times ranked

7495  
citing authors

#	ARTICLE	IF	CITATIONS
1	Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e945-e956.	4.4	52
2	The Intestinal Gas Questionnaire (IGQ): Psychometric validation of a new instrument for measuring gas-related symptoms and their impact on daily life among general population and irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14202.	3.0	5
3	Hypnotherapy for irritable bowel syndrome: patient expectations and perceptions. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210742.	3.2	7
4	The symptom burden of Irritable Bowel Syndrome in tertiary care during the COVID-19 pandemic. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14347.	3.0	10
5	Guidelines for the Assessment of Efficacy of Clinical Hypnosis Applications. <i>International Journal of Clinical and Experimental Hypnosis</i> , 2022, 70, 104-122.	1.8	18
6	Experience and clinical efficacy of gut-directed hypnotherapy in an Asian population with refractory irritable bowel syndrome. <i>JGH Open</i> , 2022, 6, 447-453.	1.6	8
7	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. <i>Gastroenterology</i> , 2021, 160, 99-114.e3.	1.3	913
8	Six vs 12 Sessions of Gut-focused Hypnotherapy for Irritable Bowel Syndrome: A Randomized Trial. <i>Gastroenterology</i> , 2021, 160, 2605-2607.e3.	1.3	13
9	Gut-focused hypnotherapy for children and adolescents with irritable bowel syndrome. <i>Frontline Gastroenterology</i> , 2021, 12, 570-577.	1.8	15
10	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. <i>Nature Genetics</i> , 2021, 53, 1543-1552.	21.4	96
11	Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?. <i>World Journal of Hepatology</i> , 2021, 13, 1816-1827.	2.0	6
12	Stigma and irritable bowel syndrome: a taboo subject?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 607-615.	8.1	41
13	European society of neurogastroenterology and motility guidelines on functional constipation in adults. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13762.	3.0	110
14	Upper gastrointestinal vascular ectasia: an under-recognized complication of systemic sclerosis. <i>Scandinavian Journal of Rheumatology</i> , 2020, 50, 1-2.	1.1	0
15	Responses to the Letter to the Editor by Bruscianno et al.. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13981.	3.0	1
16	Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. <i>Trials</i> , 2020, 21, 122.	1.6	9
17	Abnormalities of mucosal serotonin metabolism and 5-HT <sub>3</sub> receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 538-546.	3.7	37
18	Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea—are we any closer? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 826-827.	3.7	0

#	ARTICLE	IF	CITATIONS
19	Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 517.	1.6	12
20	SKYPE HYPNOTHERAPY FOR IRRITABLE BOWEL SYNDROME: Effectiveness and Comparison with Face-to-Face Treatment. <i>International Journal of Clinical and Experimental Hypnosis</i> , 2019, 67, 69-80.	1.8	42
21	Consumption of a Fermented Milk Product Containing Bifidobacterium lactis CNCM I-2494 in Women Complaining of Minor Digestive Symptoms: Rapid Response Which Is Independent of Dietary Fibre Intake or Physical Activity. <i>Nutrients</i> , 2019, 11, 92.	4.1	14
22	Gut-focused hypnotherapy for Functional Gastrointestinal Disorders: Evidence-base, practical aspects, and the Manchester Protocol. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13573.	3.0	43
23	Availability of over-the-counter laxatives should not be restricted. <i>BMJ: British Medical Journal</i> , 2019, 364, l51.	2.3	0
24	OWE-09...Outcomes of gut-focused hypnotherapy in school children and adolescents with severe refractory Irritable Bowel Syndrome. , 2019, , .		0
25	Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 20-31.	8.1	74
26	Dietary Lectin exclusion: The next big food trend?. <i>World Journal of Gastroenterology</i> , 2019, 25, 2973-2976.	3.3	9
27	Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidence-based international consensus. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1054-1070.	3.7	101
28	The short-term effects of posterior tibial nerve stimulation on anorectal physiology in patients with faecal incontinence: a single centre experience. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878611.	3.2	10
29	Minor digestive symptoms and their impact in the general population: a cluster analysis approach. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481876881.	3.2	8
30	Abdominal distension in health and irritable bowel syndrome: The effect of bladder filling. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13437.	3.0	2
31	Editorial: preventing unnecessary investigation and surgery in the irritable bowel syndrome – the critical role of the general practitioner. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1558-1559.	3.7	3
32	A randomised controlled trial, cost-effectiveness and process evaluation of the implementation of self-management for chronic gastrointestinal disorders in primary care, and linked projects on identification and risk assessment. <i>Programme Grants for Applied Research</i> , 2018, 6, 1-154.	1.0	4
33	Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. <i>United European Gastroenterology Journal</i> , 2017, 5, 773-788.	3.8	81
34	The global impact of IBS: time to think about IBS-specific models of care?. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 727-736.	3.2	33
35	Systematic review and meta-analysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 74-88.	3.2	23
36	Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. <i>Gastroenterology</i> , 2016, 150, 1481-1491.	1.3	400

#	ARTICLE	IF	CITATIONS
37	Centrally Mediated Disorders of Gastrointestinal Pain. <i>Gastroenterology</i> , 2016, 150, 1408-1419.	1.3	102
38	Novel pharmacological therapies for irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 807-815.	3.0	18
39	A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). <i>Gut</i> , 2016, 65, 91-99.	12.1	85
40	Effect of the probiotic strain <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> , BB-12 <sup>®</sup> , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. <i>British Journal of Nutrition</i> , 2015, 114, 1638-1646.	2.3	58
41	Letter: efficacy of hypnotherapy in one thousand patients with irritable bowel syndrome - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1223-1224.	3.7	1
42	PWE-251 Diagnosis and management of moderate-to-severe irritable bowel syndrome with constipation (IBS-C) in the UK: the IBIS-C study. <i>Gut</i> , 2015, 64, A323.1-A323.	12.1	0
43	The Intestinal Gas Questionnaire: development of a new instrument for measuring gas-related symptoms and their impact on daily life. <i>Neurogastroenterology and Motility</i> , 2015, 27, 885-898.	3.0	9
44	OC-066 Economic and quality-of-life burden of moderate-to-severe irritable bowel syndrome with constipation (ibs-c) in the uk: the ibis-c study. <i>Gut</i> , 2015, 64, A33.2-A34.	12.1	1
45	The continuing dilemma of chronic appendicitis. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 112-113.	3.2	1
46	An exploration of the barriers to the confident diagnosis of irritable bowel syndrome: A survey among general practitioners, gastroenterologists and experts in five European countries. <i>United European Gastroenterology Journal</i> , 2015, 3, 39-52.	3.8	16
47	Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 844-855.	3.7	85
48	Managing irritable bowel syndrome in primary care. <i>Practitioner</i> , 2015, 259, 21-4, 2-3.	0.3	3
49	Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit. <i>Gut</i> , 2014, 63, 753-760.	12.1	70
50	OC-069...Mesalazine For Treatment Of Diarrhoea-predominant Irritable Bowel Syndrome (ibs-d): A Multi-centre, Parallel Group, Randomised Placebo Controlled Trial: Abstract OC-069 Table 1. <i>Gut</i> , 2014, 63, A34-A34.	12.1	0
51	Genetic variants in <i>CDC42</i> and <i>NXPH1</i> as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. <i>Gut</i> , 2014, 63, 1103-1111.	12.1	49
52	PWE-180...A Survey Evaluating General Practitioners <sup>™</sup> , Gastroenterologists <sup>™</sup> And Experts <sup>™</sup> Diagnostic Approaches To Inflammatory Bowel Disease, Irritable Bowel Syndrome And Chronic Constipation In Five European Countries: Abstract PWE-180 Table 1. <i>Gut</i> , 2014, 63, A204.2-A205.	12.1	0
53	Avoiding analgesic escalation and excessive healthcare utilization in severe irritable bowel syndrome: a role for intramuscular anticholinergics?. <i>Therapeutic Advances in Gastroenterology</i> , 2014, 7, 232-237.	3.2	8
54	A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. <i>Gut</i> , 2014, 63, 1617-1625.	12.1	187

#	ARTICLE	IF	CITATIONS
55	Letter: using pictures to improve communication between doctor and patient in functional gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1364-1364.	3.7	5
56	Faecal incontinenceâ€”the hidden scourge of irritable bowel syndrome: a cross-sectional study. <i>BMJ Open Gastroenterology</i> , 2014, 1, e000002.	2.7	29
57	Changes of the human gut microbiome induced by a fermented milk product. <i>Scientific Reports</i> , 2014, 4, 6328.	3.3	217
58	Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 864-886.	3.7	168
59	Intestinal microbiota in functional bowel disorders: a Rome foundation report. <i>Gut</i> , 2013, 62, 159-176.	12.1	776
60	Hypnotherapy: first line treatment for children with irritable bowel syndrome?. <i>Archives of Disease in Childhood</i> , 2013, 98, 243-244.	1.9	8
61	PWE-052â€”Phenotyping the early morning rush (EMR) in patients with diarrhoea predominant irritable bowel syndrome (IBS-D). <i>Gut</i> , 2012, 61, A318.1-A318.	12.1	1
62	Visceral hypersensitivity in endometriosis: a new target for treatment?. <i>Gut</i> , 2012, 61, 367-372.	12.1	64
63	OC-091â€”Ondansetron slows transit and improves stool consistency in patients with diarrhoea predominant irritable bowel syndrome. <i>Gut</i> , 2012, 61, A39.3-A40.	12.1	0
64	Unraveling functional abdominal bloating and distension: the role of thoracoâ€”abdominal accommodation and a physical sign to aid its detection. <i>Neurogastroenterology and Motility</i> , 2012, 24, 301-304.	3.0	3
65	Severity in Irritable Bowel Syndrome: A Rome Foundation Working Team Report. <i>American Journal of Gastroenterology</i> , 2011, 106, 1749-1759.	0.4	182
66	Identifying and testing candidate genes underlying the inflammatory basis of irritable bowel syndrome. <i>Gut</i> , 2011, 60, A164-A164.	12.1	3
67	A randomised controlled trial on hypnotherapy for irritable bowel syndrome: design and methodological challenges (the IMAGINE study). <i>BMC Gastroenterology</i> , 2011, 11, 137.	2.0	13
68	5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene and irritable bowel syndrome: effect of bowel habit and sex. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 856-861.	1.6	42
69	The Manchester Color Wheel: development of a novel way of identifying color choice and its validation in healthy, anxious and depressed individuals. <i>BMC Medical Research Methodology</i> , 2010, 10, 12.	3.1	49
70	Mood color choice helps to predict response to hypnotherapy in patients with irritable bowel syndrome. <i>BMC Complementary and Alternative Medicine</i> , 2010, 10, 75.	3.7	18
71	Reactivity to images in health and irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 131-142.	3.7	20
72	The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 811-820.	3.7	155

#	ARTICLE	IF	CITATIONS
73	Review: Do probiotics improve symptoms in patients with irritable bowel syndrome?. Therapeutic Advances in Gastroenterology, 2009, 2, S37-S44.	3.2	23
74	Behavioral therapy for IBS. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 148-149.	17.8	8
75	Hypnotherapy for Functional Gastrointestinal Disorders: A Review. International Journal of Clinical and Experimental Hypnosis, 2009, 57, 279-292.	1.8	55
76	Clinical trial: the effects of a fermented milk product containing <i>Bifidobacterium lactis</i> DN-1731 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, 2009, 29, 104-114.	3.7	289
77	Irritable bowel syndrome in the elderly: An overlooked problem?. Digestive and Liver Disease, 2009, 41, 721-724.	0.9	25
78	Using Art to Help Understand the Imagery of Irritable Bowel Syndrome and Its Response to Hypnotherapy. International Journal of Clinical and Experimental Hypnosis, 2009, 57, 162-173.	1.8	26
79	Bloating and Distention in Irritable Bowel Syndrome: The Role of Visceral Sensation. Gastroenterology, 2008, 134, 1882-1889.	1.3	96
80	Hypnotherapy for non-cardiac chest pain: long-term follow-up. Gut, 2007, 56, 1643-1643.	12.1	25
81	Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut, 2007, 56, 1770-1798.	12.1	677
82	Altered 5-Hydroxytryptamine Signaling in Patients With Constipation- and Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology, 2006, 130, 34-43.	1.3	304
83	Relationship of Abdominal Bloating to Distention in Irritable Bowel Syndrome and Effect of Bowel Habit. Gastroenterology, 2006, 131, 1003-1010.	1.3	124
84	Efficacy of an Encapsulated Probiotic <i>Bifidobacterium infantis</i> 35624 in Women with Irritable Bowel Syndrome. American Journal of Gastroenterology, 2006, 101, 1581-1590.	0.4	739
85	Irritable bowel syndrome: diagnosis and management. BMJ: British Medical Journal, 2006, 332, 280-283.	2.3	71
86	Effective Management of Irritable Bowel syndrome – the Manchester Model. International Journal of Clinical and Experimental Hypnosis, 2006, 54, 21-26.	1.8	38
87	Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy. Gut, 2006, 55, 1403-1408.	12.1	127
88	FAQs: irritable bowel syndrome. Practitioner, 2006, 250, 29-30, 32.	0.3	0
89	Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterology and Motility, 2005, 17, 500-511.	3.0	66
90	Review article: the history of hypnotherapy and its role in the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2005, 22, 1061-1067.	3.7	45

#	ARTICLE	IF	CITATIONS
91	Dietary treatment of the irritable bowel syndrome. <i>Current Treatment Options in Gastroenterology</i> , 2004, 7, 307-316.	0.8	14
92	Suicidal ideation in patients with irritable bowel syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 1064-1068.	4.4	97
93	Cognitive change in patients undergoing hypnotherapy for irritable bowel syndrome. <i>Journal of Psychosomatic Research</i> , 2004, 56, 271-278.	2.6	98
94	The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40â€f000 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 643-650.	3.7	654
95	Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 635-642.	3.7	130
96	Long term benefits of hypnotherapy for irritable bowel syndrome. <i>Gut</i> , 2003, 52, 1623-1629.	12.1	228
97	Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. <i>American Journal of Gastroenterology</i> , 2002, 97, 954-961.	0.4	195
98	A device for 24 hour ambulatory monitoring of abdominal girth using inductive plethysmography. <i>Physiological Measurement</i> , 2002, 23, 661-670.	2.1	25
99	The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. <i>Gut</i> , 2002, 50, 471-474.	12.1	200
100	Visceral sensation and emotion: a study using hypnosis. <i>Gut</i> , 2002, 51, 701-704.	12.1	67
101	Long-term improvement in functional dyspepsia using hypnotherapy. <i>Gastroenterology</i> , 2002, 123, 1778-1785.	1.3	244
102	Quality of Life in Irritable Bowel Syndrome. <i>Pharmacoeconomics</i> , 2001, 19, 643-653.	3.3	80
103	High prevalence of irritable bowel syndrome in patients attending urological outpatient departments. <i>Digestive Diseases and Sciences</i> , 1997, 42, 404-407.	2.3	54
104	The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. <i>Alimentary Pharmacology and Therapeutics</i> , 1997, 11, 395-402.	3.7	1,186
105	Syptomatology, quality of life and economic features of irritable bowel syndromeâ€”the effect of hypnotherapy. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 91-95.	3.7	126
106	Bran and irritable bowel syndrome: time for reappraisal. <i>Lancet, The</i> , 1994, 344, 39-40.	13.7	271
107	Physiological effects of emotion: assessment via hypnosis. <i>Lancet, The</i> , 1992, 340, 69-72.	13.7	134
108	More accurate diagnosis of irritable bowel syndrome by the use of 'non-colonic' symptomatology.. <i>Gut</i> , 1991, 32, 784-786.	12.1	97

#	ARTICLE	IF	CITATIONS
109	Changes in rectal sensitivity after hypnotherapy in patients with irritable bowel syndrome.. Gut, 1990, 31, 896-898.	12.1	139
110	Gynaecological consultation in patients with the irritable bowel syndrome.. Gut, 1989, 30, 996-998.	12.1	79
111	Ranking of symptoms by patients with the irritable bowel syndrome.. BMJ: British Medical Journal, 1989, 299, 1138-1138.	2.3	90
112	Irritable bowel syndrome in the gynecological clinic. Digestive Diseases and Sciences, 1989, 34, 1820-1824.	2.3	105
113	Severe sexual dysfunction in women with the irritable bowel syndrome: comparison with inflammatory bowel disease and duodenal ulceration.. BMJ: British Medical Journal, 1987, 295, 577-578.	2.3	72
114	Non-colonic features of irritable bowel syndrome.. Gut, 1986, 27, 37-40.	12.1	427
115	Bladder smooth muscle dysfunction in patients with irritable bowel syndrome.. Gut, 1986, 27, 1014-1017.	12.1	125
116	CONTROLLED TRIAL OF HYPNOTHERAPY IN THE TREATMENT OF SEVERE REFRACTORY IRRITABLE-BOWEL SYNDROME. Lancet, The, 1984, 324, 1232-1234.	13.7	456